Answers are grounded in this paper and cite their sources.
Background and purpose: We analyzed the clinical manifestations of children with myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab) disease in Central South China. Methods: A retrospective study of children (0–14 years old) with MOG-Ab disease in Central South China was carried out from January 2015 to October 2018. Demographics, clinical features, treatment, and outcome were reviewed. Results: Twenty-five patients with MOG-Ab disease were enrolled (onset age from 3 years to 12.4 years old; median age, 6.6 years; 13 females). The median follow-up period was 15 months (range 7-63 months). Fever (47.4%), encephalopathy (47.4%), and lesions on white matter and/or deep gray matter (52.6%) was most frequent in children under 9 years old, while opitic neuritis (ON) (66.7%), and lesions on spinal cord and/or optic (50%) was most frequent in children more than 9 years old. Till the last follow-up, 10 (40%) patients with MOG-Ab had multiphasic courses while 15 (60%) had a monophasic course, and the mean follow-up time had significant difference (10.67 to 31 months, p=0.0001). Disease-modifying drugs were used at least once in 14/25 (56%) patients with rituximab (RTX) or/and azathioprine (AZP) or mycophenolate mofetil (MMF). The annualized relapse rate before and during treatment was 2.4 (0.67-8.22) and 0 (0-3.43) (p 9 years). Disease-modifying drugs, such as AZA, MMF or RTX, can reduce ARR.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: